# KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

> **NCT06767046** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Corregene Biotechnology Co., Ltd** · enrollment: 8 (actual)

## Conditions studied

- Colorectal
- Pancreatic
- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** KRAS-specific Autologous TCR-T cell injection

## Key facts

- **NCT ID:** NCT06767046
- **Lead sponsor:** Corregene Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-18
- **Primary completion:** 2028-11-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06767046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06767046, "KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06767046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*